Got $2,000? 4 Top Stocks to Buy This Month

Canadians with only $2,000 in capital can create a diversified portfolio that could deliver substantial gains. The top but affordable buys are Alcanna stock, BELLUS Health stock, Cineplex stock, and Diversified Royalty stock.

| More on:

In alphabetical order, what do Alcanna (TSX: CLIQ), BELLUS Health (TSX:BLU)(NASDAQ:BLU), Cineplex (TSX:CGX), and Diversified Royalty (TSX:DIV) have in common? Well, these four stocks are the top buys on the TSX in May 2021. If you have $2,000 to invest today, you can purchase $500 worth of each stock and expect substantial gains.

Specialty retail

Alcanna is a premier retailer of alcohol and highly regulated controlled substances (wines, beers, spirits, and cannabis) in North America. The $252.7 million company from Edmonton is a dynamic organization with 250 liquor and cannabis retail outlets.

As of May 21, 2021, the share price is $6.98, and thus far, current investors are enjoying a 17.91% gain. Market analysts recommend a strong buy rating and foresee further gain of 97% to $13.75 in the next 12 months. Alcanna’s trailing one-year price return in 220.18%.

In Q1 2021 (quarter ended March 31, 2021), total sales grew by 2.8% to $142.2 million versus Q1 2020. From a net loss of $9.2 million, Alcanna reported $47.6 million in net earnings. During the same quarter, the company partnered with YSS to form Nova Cannabis, a new discount-focused cannabis retailer.

Growth driver in the making

While BELLUS Health trades at only $4.66 per share, analysts forecast a 157.5% price appreciation to $12. Your $500 could potentially grow to $787.50 in one year. The healthcare stock is also among the better performers in 2021 with its 21.67% year-to-date gain.

The $365 million clinical-stage biopharmaceutical firm develop novel therapeutics to treat chronic cough and other hypersensitization-related disorders. Its lead product candidate is BLU-5397, a highly selective P2X3 antagonist. Once it passes clinical trials and receives regulatory approval, BLU-5397 may be the viable treatment option for patients suffering from chronic cough or chronic pruritus associated with atopic dermatitis.

A faster-than-expected recovery

The Cineplex stock is recovering from the pandemic faster than expected. Its year-to-date gain is 51.02%, and according to analysts, the current share price of $14 could hit $17 or a 21.4% upside in the near term. COVID-19’s impact on the business is brutal because the most prominent theatre operator in Canada lost its propensity to generate revenues as it had in the past.

Unlike in the U.S., cinemas in Canada have yet to enjoy a return to business. Traditional cinemas are also losing a lot of ground from streaming services like Amazon and Netflix. Despite the challenges and threats to the movie exhibition industry, investors are happy with Cineplex’s remarkable comeback.

Pure dividend play

Diversified Royalty is a cheap dividend play. At $2.51 per share, would-be investors can partake of the juicy 7.97% dividend yield. Don’t expect much capital gain, although the royalty stock is up 9.03% year to date.

The $305 million multi-royalty corporation from Vancouver acquires royalties from multi-location businesses and franchisors in North America. Currently, Diversified Royalty owns the trademarks to AIR MILES, Mr. Lube, Mr. Mikes, Nurse Next Door, Sutton, and Oxford Learning Centres.

In Q1 2021 (three months ended March 31, 2021), the royalty firm’s top line increased 4.8% to $7.6 million compared to Q1 2020. Notably, net income for the quarter was $4.1 million versus the net loss of $11.7 million in the same period last year.

Diversified portfolio

Canadians with just $2,000 to invest can build a diversified portfolio. All four stocks display respectable performances in 2021, notwithstanding the continuing pandemic.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Christopher Liew has no position in any of the stocks mentioned. David Gardner owns shares of Amazon and Netflix. Tom Gardner owns shares of Netflix. The Motley Fool owns shares of and recommends Amazon and Netflix. The Motley Fool recommends CINEPLEX INC and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon.

More on Dividend Stocks

woman looks at iPhone
Dividend Stocks

The Top 3 Canadian Dividend Stocks I Think Belong in Everyone’s Portfolio

The reliable payouts of these TSX stocks and the potential for steady capital appreciation, makes them compelling investments.

Read more »

money goes up and down in balance
Dividend Stocks

This Canadian Dividend Stock Pays 5.6%

This TSX dividend star is worth watching closely if you are on the hunt for reliable long-term returns.

Read more »

Stethoscope with dollar shaped cord
Dividend Stocks

Why This Canadian REIT Could Be a Buy-and-Hold Forever Stock

Northwest Healthcare Properties REIT is yielding 6.9% as it benefits from a relatively low-risk business model.

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Top TSX Stocks

TFSA Investors: 3 Dividend Stocks Worth Holding Forever

Here's a look at a trio of TFSA picks for passive income that can last a lifetime.

Read more »

A bull and bear face off.
Dividend Stocks

Is TC Energy Stock a Good Buy?

After increasing its dividends annually for over a quarter of a century, TC Energy (TSX:TRP) might still be an excellent…

Read more »

customer uses bank ATM
Dividend Stocks

Got $1,000? BNS Stock Can Turn It Into a Passive-Income Stream

Want to build a passive-income stream? If you’re starting with a $1,000 pool, Scotiabank can be the anchor for your…

Read more »

data analyze research
Dividend Stocks

The Best Stocks to Invest $7,000 in Right Now

As volatility keeps investors cautious, these two Canadian stocks remain solid options for putting $7,000 to work with confidence.

Read more »

woman checks off all the boxes
Dividend Stocks

The Smartest Dividend Stocks to Buy With $2,000 Right Now

These two stocks look like world-class winners but are being overlooked by dividend investors who may be focused on other…

Read more »